Key features and details | |
Cat. No. | MABL-2039 |
Name | Anti-IL-17A mAbs |
Clone No. | AFD- MM17F3 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | Blocking, therapeutic, ELISA |
Species Reactivity | Mouse |
Basic Information | |
Specificity | This antibody is highly specific for murine IL-17A; in ELISA analysis, no cross-reactivity with IL‐17B, IL‐17C, IL‐17D, IL‐17E or IL‐17F was observed. |
Alternative Name | Interleukin-17A; IL17A; Cytotoxic T-lymphocyte-associated antigen 8; CTLA-8 |
UniProt | Q62386 |
Immunogen | This antibody was raised by immunising C57Bl/6 mice with IL-17A cross-linked to ovalbumin to generate a highly immunogenic complex. |
Application Notes | The specificity of this antibody has been confirmed in ELISA analysis (Uyttenhove et al, 2006). This antibody inhibits IL‐17A‐induced IL‐6 production by a Cl1D fibroblastic cell line in vitro (Uyttenhove et al, 2006). This antibody has been shown to prevent experimental autoimmune encephalomyelitis (EAE) disease development in vivo (Uyttenhove et al, 2006), as well as protecting C57Bl/6 mice from myelin oligdendrocyte glycoprotein (MOG)-induced EAE (Uyttenhove et al, 2007). Additionally, administration of this antibody inhibits collagen-induced arthritis (CIA) in IFN-γ receptor knockout mice (Kelchtermans et al, 2009). |
Antibody First Published | Uyttenhove et al. Development of an anti‐IL‐17A auto‐vaccine that prevents experimental auto‐immune encephalomyelitis Eur J Immunol. 2006 Nov;36(11):2868-74 PMID:17048276 |
Note on publication | Describes the original generation of this antibody, and the characterisation of its IL- 17A-inhibitory activity. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
